definiens: shall mean the earliest of ( a ) ( i ) October 1, 2032 if Par is entitled to and has not f orfeited First - Filer Exclusivity as of April 1, 203 2, or ( ii ) April 1, 2032 if Par is not entitled to First- Filer Exclusivity or if Par has forfeited First Fil er Exclusivity as of such date, ( b ) the date of one or more final decisi on(s ) of a U.S. court or the U.S. Patent Trial and Appeal Board from which no appeal has been or can be taken ( othe r than a petition to the U.S. Supreme Court for a w rit of certiorari ) holding that all claims of the OMIDRIA Patents asserted by [COMPANY] and adjudicated at the t ime of such final decision(s ) are invalid or unenforceable, ( c ) the date on which all the OMIDRIA Patents hav e been permanently abandoned, expired, or delisted from th e FDA ’s Orange Book ; provided that all periods of Regulatory Exclusivity have expired, ( d ) the date o n which any Third Party generic manufacturer ( other than Par ) launches a Generic OMIDRIA Product in the Terr itory under a license or other agreement with Omero s or any of its Affiliates, and ( e ) the date on which Om eros or any of its Affiliates or a Third Party laun ches an Authorized Generic under a license or other agreeme nt with [COMPANY] or its Affiliates